By Adam Gefvert, CFA : Achillion Pharmaceuticals (NASDAQ: ACHN ) is a biotech company that focuses on developing treatments for Hepatitis C (HCV). Most of the company's value is riding on the success of its nucleotide, ACH-3422. Research suggests that if trials show that this nucleotide works only
Keryx Biopharmaceuticals ( KERX -11% ) slumps again on a 5x surge in volume. Shares are off ~ 17% from the August 28 peak of $18.48. On Friday, the FDA
By SA Transcripts : Keryx Biopharmaceuticals (NASDAQ: KERX ) Approval of Ferric Citrate Conference Call September 05, 2014 12:00 PM ET Executives Amy Sullivan - VP of Corporate Development
28% . GIGA +24% . IHT +22% . RMGN +18% . GLRI +16% . MXC +14% . IPCI +13% . Top 10 Losers: VII -12% . ESYS -10% . DGLY -9% . KERX -9% . RVLT -9% . WRLD -9% . COUP -8% . TRMR -7% . CPE -8% . Post your comment!
By Zvi Bar : On Friday, September 5, Keryx Biopharmaceuticals (NASDAQ: KERX ) received U.S. Food & Drug Administration ..... regarding the drug's safety warning, and that KERX shares will appreciate after investors realize the
Gainers: MGAM +29% . RADA +8% . HTZ +5% . Losers: HPTX -10% . WRLD -9% . KERX -8% . DGLY -6% . Post your comment!
Sept 5 (Reuters) - Keryx Biopharmaceuticals Inc won U.S. approval for its drug to lower phosphate levels in patients with chronic kidney disease (CKD), but the approval included an unexpected safety warning on the label.
My grandson in college tries to spot "opportunities" in the market. He had KERX spotted to rise today IF their new drug got approved. Well, the price moved DOWN from the open over 6% ... then the announcement
According to NASDAQ , shares of Keryx Biopharmaceuticals ( KERX -6.2% ) will resume trading at 1:40 pm ET. Trading was halted earlier today pending the dissemination of the news of the FDA's approval of ferric citrate. Post your comment!
The FDA approves Keryx Biopharmaceuticals ' ( KERX -6.2% ) ferric citrate (formerly Zerenex) for the control of serum phosphate levels in patients with chronic kidney disease